

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A method for stabilizing a soluble recombinant protein solution formulation, which comprises storing the protein solution formulation under a magnetostatic field, wherein the magnetic flux density of the magnetostatic field is 1 mT (millitesla) or more.

Claim 2. (Cancelled)

3. (Currently Amended) The method according to claim 1, wherein the soluble recombinant protein is a physiologically active protein.

4. (Original) The method according to claim 3, wherein the physiologically active protein is selected from an antibody, an enzyme, a cytokine and a hormone.

5. (Original) The method according to claim 4, wherein the physiologically active protein is a hematopoietic factor.

6. (Original) The method according to claim 5, wherein the hematopoietic factor is erythropoietin or granulocyte colony-stimulating factor.

Claim 7. (Cancelled)

8. (Currently Amended) The method according to claim 1, wherein the soluble recombinant protein solution formulation is in the form of a pre-filled syringe formulation.

Claims 9-10. (Cancelled)

11. (Currently Amended) A method for stabilizing a soluble recombinant protein-containing solution, which comprises storing the protein-containing solution under a magnetostatic field.

12. (Currently Amended) The method according to claim 11, wherein the soluble recombinant protein-containing solution is a bulk solution for protein production.

Claims 13-18. (Cancelled)

19. (Currently Amended) The method of claim 1, wherein the soluble recombinant protein is an isolated and purified recombinant protein.

20. (Currently Amended) A method for stabilizing a composition consisting essentially of a soluble protein and a pharmaceutically acceptable carrier comprising storing the composition under a magnetostatic field.

21. (Currently Amended) The method according to claim 20 wherein the soluble protein is selected from the group consisting of antibodies, enzymes, cytokines, and hormones.

22. (Currently Amended) The method according to claim 20 wherein the soluble protein is a hematopoietic factor.

23. (Previously Presented) The method according to claim 22 wherein the hematopoietic factor is erythropoietin or granulocyte colony-stimulating factor.

24. (Previously Presented) The method according to claims 20 wherein the pharmaceutically acceptable carrier is water.

25. (Previously Presented) The method according to claim 1, wherein the magnetostatic field is generated by a magnet.

26. (Previously Presented) The method according to claim 11, wherein the magnetostatic field is generated by a magnet.

27. (Previously Presented) The method according to claim 20, wherein the magnetostatic field is generated by a magnet.